BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

Sue Desmond-Hellmann is stepping down after five years as CEO of the Bill & Melinda Gates Foundation . Before joining the foundation, she spent 14 years at Genentech Inc., where she helped develop cancer drugs Herceptin...
BioCentury | Jun 29, 2019

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | May 24, 2019

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Apr 6, 2019

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Apr 5, 2019
Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

Circassia said FDA approved Duaklir Pressair aclidinium bromide/formoterol fumarate to treat chronic obstructive pulmonary disease. The agency also accepted for review an sNDA for Tudorza Pressair aclidinium bromide to include on its label clinical data...
BioCentury | Mar 21, 2019
Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more...
BioCentury | Jan 17, 2019

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
BioCentury | Dec 11, 2018
Distillery Therapeutics


INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
BioCentury | Oct 11, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; tissue markers A tissue-based gene signature for quantifying immune cells could help identify populations of immune cell types as diagnostic or prognostic markers of disease. Identification of the signature, dubbed ImSig, involved...
Items per page:
1 - 10 of 117